Small-molecule estrogen-related receptor agonist · Fact sheet
SLU-PP-332
SLU-PP-332 activates estrogen-related receptors and has produced exercise-like metabolic effects in mice. It has not been established as an effective or safe substitute for exercise in humans.
What is SLU-PP-332?
Estrogen-related receptors help regulate cellular energy metabolism; their name does not mean SLU-PP-332 is an estrogen supplement. It is a small molecule, not a peptide.
Benefits people look for
Endurance, fat loss, and improved mitochondrial function are the main interests. An exercise-like gene response is not the same as the full benefits of physical activity.
What the evidence supports
- Mice showed improved exercise endurance in an initial study.
- Other mouse experiments found metabolic and cardiac effects; each result depends on its experimental model.
All research areas
- Exercise-related gene programs
- Obesity models
- Cardiac energy metabolism
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- Human side-effect frequencies and interactions have not been established in the cited evidence.
- Preclinical cardiac benefits do not establish cardiovascular safety in people.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Mostly animal or lab researchThe cited experiments involve cell systems, mouse obesity models, and mouse pressure-overload heart failure. They do not establish human efficacy or safety.
Selected research to read
Cell and mouse experiments of estrogen-related receptor activation.
Mouse obesity and metabolic outcomes.
Cell and mouse studies; not a human heart-failure trial.
FDA approval & research status
SLU-PP-332 has no FDA-approved therapeutic use. Its experimental findings should not be presented as a completed human clinical program.
No FDA-approved use is documented in the records summarized on this page.
Preclinical evidence; no FDA approval
SLU-PP-332 has no FDA-approved therapeutic use. Its experimental findings should not be presented as a completed human clinical program.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Human exposure and tolerability
- Effects on real-world function and disease outcomes
- Long-term effects of sustained receptor activation
The takeaway
SLU-PP-332 is a preclinical research compound. The phrase exercise mimetic describes a mechanism and mouse findings, not a proven human replacement for exercise.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1pubmedSLU-PP-332 and exercise capacity
Cell and mouse experiments of estrogen-related receptor activation.
- 2
- 3pubmedPan-ERR agonists in experimental heart failure
Cell and mouse studies; not a human heart-failure trial.